|
Adverse events within 7 days of administration; study participants aged 18-64 years |
||
|
Adverse event reported |
Dose 1 (%) |
Dose 2 (%) |
|
Local erythema |
3.0 |
8.9 |
|
Local swelling |
6.7 |
12.6 |
|
Pain at injection site |
86.9 |
89.9 |
|
Axillary tenderness/swelling |
11.6 |
16.2 |
|
Fatigue |
38.4 |
67.6 |
|
Headache |
35.3 |
62.8 |
|
Chills |
9.2 |
48.6 |
|
Nausea/vomiting |
9.4 |
21.4 |
|
Fever |
0.9 |
17.4 |
|
Myalgia |
23.7 |
61.6 |
|
Arthralgia |
16.6 |
45.5 |
|
Adverse events within 7 days of administration; study participants aged ≥65 years |
||
|
Adverse event reported |
Dose 1 (%) |
Dose 2 (%) |
|
Local erythema |
2.3 |
7.5 |
|
Local swelling |
4.4 |
10.8 |
|
Pain at injection site |
74.0 |
83.2 |
|
Axillary tenderness/swelling |
6.1 |
8.5 |
|
Fatigue |
33.3 |
58.3 |
|
Headache |
24.5 |
46.2 |
|
Chills |
5.4 |
30.9 |
|
Nausea/vomiting |
5.2 |
11.8 |
|
Fever |
0.3 |
10.0 |
|
Myalgia |
19.7 |
47.1 |
|
Arthralgia |
16.4 |
35.0 |
|
Adapted from N Engl J Med. 2020 Dec 30. doi: 10.1056/NEJMoa2035389 and Product Monograph: Moderna COVID-19 Vaccine, mRNA-1273 SARS-CoV-2 vaccine. |
||